Introduction

Flutamide is a nonsteroidal pure antiandrogen drug (toluidine derivative, structurally associated to bicalutamide and nilutamide), which perform its action by inhibiting the uptake and/or binding of dihydrotestosterone to the target cell receptor that leads to alter the interfering with the androgen action. It blocks the action of both endogenous and exogenous testosterone by binding to the androgen receptor, thus flutamide administration results in elevations of plasma testosterone and estradiol [1]. However, it was reported that it is a potent inhibitor of testosterone-stimulated prostatic DNA synthesis. 2-Hydroxyflutamide, an active metabolite of flutamide competitively blocks the dihydrotestosterone binding at androgen receptors, which results in the formation of inactive complexes that could not be translocate into the cell nucleus. This property is significantly useful to arrest the growth of tumour cell or transient tumour regression [2]. Absorption, distribution, and excretion of flutamide is very rapid and absorbed completely. In addition, it is rapidly and extensively metabolized with only 2.5% of plasma radioactivity of 1 hour after administration. The biological half-life of the alpha-hydroxylated metabolite of flutamide is approximately 6 hours. Flutamide, as an anti-androgens action used to treat prostate cancer in men, by blocking the effects of testosterone that helps prostate cancer to grow and also significantly used with other medications for radiation treatments [3]. Flutamide is administered and preferred orally, while it is 95% plasma protein-bound and seems to concentrate in the prostate. The data suggested that flutamide undergoes rapid metabolism to a variety of compounds. However, 95% of an oral dose is excreted by the kidneys. Hemodialysis cannot remove it due to its high protein binding. It might have some side effects because this is commonly used with other medications, such as hot flashes, diarrhoea and nausea, loss of sexual interest/ability, vomiting, and enlargement of male breasts. However, drowsiness is one of
the less common side effects, while diarrhoea is a common side
effect. The rate of absorption and mechanism of action depends
upon various factors of drugs such as its solubility, stability, phar-
macokinetics and bioavailability [4,5]. However, physicochemical
properties of any pharmaceuticals are very important in the dif-
ferent role for its biological profile. Therefore, in order to improve
the physicochemical profile such as such as particle size, crystalline
structure, crystallite size, surface area, etc., research has been car-
ried to alter the physicochemical properties.

The Biofield Energy Treatment is considered as an emerging
field as it is an integral healthcare approach including the
increasing beneficial effects of Complementary and Alternative
Medicine (CAM) therapies, against various health conditions
[6,7]. National Institute of Health (NIH) recommend and included
various Energy Healing therapies such as natural products, yoga,
deep breathing, meditation, homeopathy, progressive relaxation,
acupressure, acupuncture, hypnotherapy, relaxation techniques,
healing touch, pilates, Ayurvedic medicine, traditional Chinese
herbs and medicines, Reiki, cranial sacral therapy, etc. under CAM
category and these are accepted by most of the U.S. population
with several advantages [8,9]. Similarly, the Biofield Energy
Healing (the Trivedi Effect)® has also been popular worldwide
due to its remarkable impact on the nonliving materials as well
as the living organisms. The Trivedi Effect®-Consciousness
Energy Healing Treatment has been reported for its significant
impact on the physicochemical and thermal properties of various
pharmaceutical/nutraceutical compounds [10-12], plants [13,14],
altered characteristics in microbiology [15-17], metals, ceramics,
and polymers [18,19], livestock [20], biotechnology [21], and
skin health [22]. Thus, this study was aimed to determine the
effect of the Biofield Energy Treatment (Trivedi Effect)® on the
physicochemical and thermal properties of flutamide by using
various analytical techniques such as, particle size analysis (PSA),
powder X-ray diffraction (PXRD), thermogravimetric analysis
(TGA), and differential scanning calorimetry (DSC).

Materials and Methods

Chemicals and reagents

Flutamide was purchased from Tokyo Chemical Industry Co.
Ltd. All other chemicals used during the experiments were of ana-
lytical grade available in India.

Consciousness energy healing treatment strategies

Flutamide, i.e., the test compound was divided into two parts.
Among both parts, one portion was denoted as control sample
that did not receive the Biofield Energy Treatment. Besides, the
other part of flutamide was considered as the treated part that
received the Energy of Consciousness Healing Treatment by
the renowned Biofield Energy Healer, Alice Branton (USA), and named
as the Biofield Energy Treated sample. In the process of Biofield
Energy Treatment, the sample was kept under the standard lab-
oratory conditions, and the Biofield Energy Healer provided the
Trivedi Effect®- Energy of Consciousness Healing Treatment to
the sample, remotely, for 3 minutes through the Unique Energy
Transmission process. On the other hand, the control flutamide
was subjected to a "sham" healer under the similar laboratory
conditions, who did not have any knowledge about the Biofield
Energy Healing Treatment. Consequently, the control as well as
Biofield Energy Treated flutamide samples were kept in similar
sealed conditions and further characterized by using modern an-
alitical techniques.

Characterization

The PSA, PXRD, TGA/DTG, and DSC analysis of pyridoxine
were performed. The PSA was performed using Malvern Master-
sizer 2000, from the UK with a detection range between 0.01µm
to 3000µm using the wet method [23,24]. The PXRD analysis of
pyridoxine powder sample was performed with the help of Rigaku
MiniFlex-II Desktop X-ray diffractometer (Japan) [25,26]. The aver-
age size of crystallites was calculated from PXRD data using the
Scherrer’s formula (1)

\[ G = \frac{K\lambda}{\beta\cos\theta} \]  

Where G is the crystallite size in nm, k is the equipment con-
stant (0.94), \( \lambda \) is the radiation wavelength (0.154056nm for K
1 emission), \( \beta \) is the full-width at half maximum, and \( \theta \) is
the Bragg angle [27]. Similarly, The TGA/DTG thermograms of pyri-
doxine were obtained with the help of TGA Q50 TA instruments.
The DSC analysis of pyridoxine was performed with the help of
DSC Q200, TA instruments [23,24]. The % change in particle size,
specific surface area (SSA), peak intensity, crystallite size, melting
point, latent heat, weight loss and the maximum thermal degrada-
tion temperature (Tmax) of the Biofield Energy Treated sample was
calculated compared with the control sample using the following
equation 2:

% Change in weight loss = \( \frac{[\text{Treated} - \text{Control}]}{\text{Control}} \) * 100......(2)

Results and Discussion

Particle size analysis (PSA)

The particle size analysis of the control and Biofield Energy
Treated samples were presented in Table 1. The particle size dis-
tribution of the control sample was found at \( d_{10} = 44.31\mu m, d_{20}
= 179.98\mu m, d_{50} = 653.57\mu m, and D (4, 3) = 276.60\mu m 
However, the particle size distribution of the Biofield Energy Treated flut-
amide sample was observed at \( d_{10} = 51.32\mu m, d_{20} = 209.43\mu m,
\( d_{50} = 660.45\mu m, \) and D (4, 3) = 290.70\mu m. The result analysis
revealed that the particle size values at \( d_{10}, d_{20}, d_{50} \) and D (4, 3) in
the Biofield Energy Treated sample were significantly increased
by 15.82%, 16.36%, 1.05%, and 5.10%, respectively, compared to
the control sample.

On the other hand, the specific surface area of the Biofield
Energy Treated flutamide (0.088m²/Kg) was decreased by 14.56%
as compared with the control sample (0.103m²/Kg). The litera-
ture reported the impact of particle size distribution of drug on
The formulation development in terms of its blend uniformity, compactibility, and flowability, etc., which further affected the safety, efficacy, and the quality of the formulation [28,29]. Hence, the Biofield Energy Treated flutamide sample might help in better formulation development by improving its uniformity, flowability, and compactibility.

**Table 1**: Particle size distribution of the control and Biofield Energy Treated flutamide.

| Parameter         | \(d_{10}\) (µm) | \(d_{50}\) (µm) | \(d_{90}\) (µm) | \(D(4,3)\) (µm) | SSA (m²/g) |
|-------------------|------------------|------------------|------------------|------------------|------------|
| Control           | 44.31            | 179.98           | 653.57           | 276.6            | 0.103      |
| Biofield Treated  | 51.32            | 209.43           | 660.45           | 290.7            | 0.088      |
| Percent change    | 15.82            | 16.36            | 1.05             | 5.1              | -14.56     |

\(d_{10}\), \(d_{50}\), and \(d_{90}\): particle diameter corresponding to 10%, 50%, and 90% of the cumulative distribution, \(D(4,3)\): the average mass-volume diameter, and SSA: the specific surface area. *denotes the percentage change in the Particle size distribution of the Biofield Energy Treated sample with respect to the control sample.

**Powder X-ray Diffraction (PXRD) Analysis**

**Table 2**: PXRD data for the control and Biofield Energy Treated flutamide.

| Entry No. | Bragg angle (°2θ) | Intensity (cps) | Crystallite size (G, nm) |
|-----------|-------------------|-----------------|-------------------------|
|           | Control           | Treated         | Control                 | Treated         | % change² |
| 1         | 8.85              | 8.72            | 3489                    | 3734            | 7.02      |
| 2         | 17.42             | 17.37           | 597                     | 751             | 25.8      |
| 3         | 18.97             | 18.94           | 1735                    | 2003            | 15.45     |
| 4         | 26.21             | 26.11           | 1439                    | 1589            | 10.42     |
| 5         | 40.47             | 40.31           | 629                     | 814             | 29.41     |

²: Denotes the percentage change in the crystal size of Biofield Energy Treated sample with respect to the control sample.

The PXRD diffractograms of the control and Biofield Energy Treated flutamide samples are shown in Figure 1. There was the presence of sharp and intense peaks in the diffractograms of both the samples which indicated that both the samples are crystalline in nature. Besides, the peak intensities and the crystallite size corresponding to each characteristic peak was done for both the control and the Biofield Energy Treated sample (Table 2). The highest peak intensity (100%) was observed at 2θ equal to 8.85° (Table 2, entry 1) in the PXRD diffractogram of the control sample, while at 8.72° in the Biofield Energy Treated sample; however, the Bragg’s angle of all the characteristic peaks of the Biofield Energy Treated sample were observed to differ from the control sample. Also, the peak intensities corresponding to these characteristic diffraction peaks in the Biofield Energy Treated sample were found to be significantly increased ranging from 7.02% to 29.41% compared to the control sample. Such alterations in the peak intensities of the peaks indicated the change in the crystallinity of the Biofield Energy Treated sample as compared to the control flutamide sample.

Besides, the crystallite sizes of the Biofield Energy Treated sample corresponding to those peaks were also observed to be significantly altered ranging from -9.17% to 17.86% as compared to the control sample. Also, the Biofield Energy Treated sample showed an increase in the average crystallite size (158.5nm) by 2.84% as compared to the control sample (154.12nm). The literature reported that the alterations in the peak intensity of the crystalline compound changes based on its crystal morphology [30]. Moreover, the alterations in the complete PXRD pattern may be considered as the proof of polymorphic transitions taken place in treated flutamide sample [31,32]. Thus, the overall results indicated the alterations in the crystallinity, crystallite size, and polymorphic form of the Biofield Energy Treated flutamide sample when compared with the control sample. Such changes might ensure its better drug performance in the formulation development than the untreated flutamide.
Thermal gravimetric analysis (TGA)/ Differential thermogravimetric analysis (DTG)

The TGA thermograms of the control and Biofield Energy Treated flutamide samples displayed one step of thermal degradation (Figure 2). The results revealed 2.21% increase in the total weight loss of the Biofield Energy Treated flutamide as compared with the control sample (Table 3). Also, the residue amount of the treated flutamide sample was reduced significantly by 64.16% when compared to the control sample (Table 3).

Table 3: TGA/DTG data of the control and Biofield Energy Treated samples of flutamide.

| Sample                 | TGA                      | DTG                      |
|------------------------|--------------------------|--------------------------|
|                        | Total weight loss (%)    | Residue %                |
| Control                | 96.677                   | 3.323                    |
| Biofield Energy Treated| 98.809                   | 1.191                    |
| % Change*              | 2.21                     | -64.16                   |
| T_{\text{max}} (°C)    | 227.25                   | 250.35                   |

*denotes the percentage change of the Biofield Energy Treated sample with respect to the control sample.

The DTG thermograms of the control and Biofield Energy Treated sample showed a single peak (Figure 3). The results revealed that the onset of thermal degradation taken place at 134.68°C in the control flutamide sample, while it started earlier in the Biofield Energy Treated sample i.e., at 103.41°C. However, the maximum thermal degradation temperature (T_{\text{max}}) of the treated flutamide sample was significantly increased by 10.16% as compared with the control sample (Table 3). Thus, the overall, TGA/DTG results showed that the thermal stability of the Biofield Energy Treated sample was significantly decreased as compared with the control flutamide sample.

Differential scanning calorimetry (DSC) analysis

The DSC thermograms of both the control and the Biofield Energy Treated flutamide samples were shown in Figure 4 and the results were used to determine the melting and other thermal behaviours of the flutamide sample [33]. A sharp endothermic peak was evident in the thermograms of both the samples which are considered as the melting temperature of the samples. The peak was observed in the control sample at 113.23°C; while it was slightly decreased to 112.58°C in the Biofield Energy Treated flutamide sample. Moreover, the latent heat of fusion (ΔH) of the con-
Concentration sample was found as 107.2 J/g; whereas it was decreased to 97.15 J/g in the Biofield Energy Treated sample. Hence, the results revealed a reduction in the melting point and the ΔH\text{fus}\text{ion} of the Biofield Energy Treated flutamide by 0.57% and 9.37%, respectively as compared to the control sample (Table 4). It is presumed that there might be some alterations in the molecular chains and the crystallization structure of the flutamide [33] due to the Biofield Energy Treatment that may cause the changes in the melting temperature and ΔH of the treated flutamide.

Conclusion

The study revealed that the Trivedi Effect®-Consciousness Energy Healing Treatment showed a significant impact on the particle size distribution, crystallite sizes, peak intensities, and the thermal properties of flutamide. The particle size values of the Alice’s Biofield Energy Treated flutamide were increased significantly by 15.82%, 16.36%, 1.05%, and 5.10% at d_{90}, d_{50}, d_{10}, and D (4, 3), respectively compared to the control sample. The specific surface area of the Biofield Energy Treated flutamide were increased by 2.21% in TGA; whereas, the residue amount was significantly reduced by 64.16% as compared to the control sample. The DTG study showed that the T_{max} of the Biofield Energy Treated flutamide sample was significantly improved by 10.16% compared with the control sample. The Biofield Energy Treated sample revealed that the melting temperature and ΔH\text{fus}\text{ion} were decreased by 0.57% and 9.37%, respectively as compared to the untreated flutamide sample. Thus, the thermal analysis indicated the less thermal stability of the Biofield Energy Treated sample as compared to the control sample. Overall, the Trivedi Effect®-Consciousness Energy Healing Treatment poses its impact on the flutamide sample, which might generate its new polymorphic form with altered crystallinity, particle size, and thermal stability. Such alterations in the Trivedi Effect® Treated flutamide may confirm its better designing in the form of nutraceutical and pharmaceutical formulations by providing better compactibility, flowability, and content uniformity, which might be used to offer better therapeutic response against prostate cancer; androgen-dependent skin and hair conditions including acne, seborrhea, hirsutism, and scalp hair loss, hyperandrogenism, as well useful for feminizing hormone therapy aimed at transgender women.

Acknowledgements

The authors are grateful to Central Leather Research Institute, SIPRA Lab. Ltd., Trivedi Science, Trivedi Global, Inc., Trivedi Testimonials, and Trivedi Master Wellness for their assistance and support during this work.

References

1. Sufrin G, Coffey DS (1976) Flutamide. Mechanism of action of a new nonsteroidal antiandrogen. Invest Urol 13(6): 429-434.
2. Labrie F (1993) Mechanism of action and pure antiandrogenic properties of flutamide. Cancer 72(12): 3816-3827.
3. Marchetti B, Labrie F (1988) Characteristics of flutamide action on prostatic and testicular functions in the rat. J Steroid Biochem 29(6): 691-698.
4. Miranda A, Caraballo I, Millán M (2002) Stability study of flutamide in solid state and in aqueous solution. Drug Dev Ind Pharm 28(4): 413-422.
5. Anjum S, Swan SK, Lambrecht Lj, Radwanski R, Catler DL, et al. (1999) Pharmacokinetics of flutamide in patients with renal insufficiency. Br J Clin Pharmacol 47(1): 43-47.
6. Frass M, Strassl RP, Priehs H, Müllner M, Kundi M (2012) Use and acceptance of complementary and alternative medicine among the general population and medical personnel: A systematic review. Ochsner J 12(1): 45-56.
7. Barnes PM, Bloom B, Nahin RL (2008) Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Rep 12: 1-23.
8. Rubik B (2002) The biofield hypothesis: Its biophysical basis and role in medicine. J Altern Complement Med 8(6): 703-717.
9. Koithan M (2009) Introducing complementary and alternative therapies. J Nurse Pract 5(1): 18-20.
10. Trivedi MK, Branton A, Trivedi D, Nayak G, Nykvist CD, et al. (2017) Evaluation of the Trivedi Effect®: Energy of Consciousness Energy Healing Treatment on the physical, spectral, and thermal properties of zinc chloride. American Journal of Life Sciences 5(1): 11-20.
11. Trivedi MK, Patil S, Shettigar H, Bairwa K, Jana S (2015) Spectroscopic characterization of biofield treated metronidazole and tinidazole. Med chem 5(7): 340-344.
12. Trivedi MK, Branton A, Trivedi D, Shettigar H, Bairwa K, et al. (2015) Fourier transform infrared and ultraviolet-visible spectroscopic characterization of biofield treated salicylic acid and sparfloxacin. Nat Prod Chem Res 3: 186.
13. Trivedi MK, Branton A, Trivedi D, Nayak G, Mondal SC, et al. (2015) Morphological characterization, quality, yield and DNA fingerprinting of biofield energy treated alphonso mango (Mangifera indica L.). Journal of Food and Nutrition Sciences 3: 245-250.
14. Trivedi MK, Branton A, Trivedi D, Nayak G, Mondal SC, et al. (2015) Evaluation of biochemical marker- Glutathione and DNA fingerprinting of biofield energy treated Oryza sativa. American Journal of Bio Science 3(6): 243-248.
15. Trivedi MK, Patil S, Shettigar H, Mondal SC, Jana S (2015) Evaluation of biofield modality on viral load of Hepatitis B and C viruses. J Antivir Antiretrovir 7: 083-088.
16. Trivedi MK, Patil S, Shettigar H, Mondal SC, Jana S (2015) An impact of biofield treatment: Antimycobacterial susceptibility potential using BACTEC 460/MGIT-TB System. Mycobact Dis 5: 189.
17. Trivedi MK, Branton A, Trivedi D, Nayak G, Charan S, et al. (2015) Phe-notyping and 16S rDNA analysis after biofield treatment on Citrobacter braakii: A urinary pathogen. J Clin Med Genom 3: 129.
18. Trivedi MK, Tallapragada RM, Branton A, Trivedi D, Nayak G, et al. (2015) The potential impact of biofield energy treatment on the physical and thermal properties of silver oxide powder. International Journal of Biomedical Science and Engineering 5(5): 62-68.
19. Trivedi MK, Tallapragada RM, Branton A, Trivedi D, Nayak G, et al. (2015) Analysis of physical, thermal, and structural properties of biofield energy treated molybdenum dioxide. International Journal of Materials Science and Applications 4(5): 354-359.
20. Trivedi MK, Branton A, Trivedi D, Nayak G, Mondal SC (2015) Effect of biofield treated energized water on the growth and health status in chicken (Gallus gallus domesticus). Poult Fish Wildl Sci 13: 140.
21. Nayak G, Altekar N (2015) Effect of biofield treatment on plant growth and adaptation. J Environ Health Sci 1: 1-9.
22. Kinney JP, Trivedi MK, Branton A, Trivedi D, Nayak G, et al. (2017) Ov erall skin health potential of the biofield energy healing based herbomineral formulation using various skin parameters. American Journal of Life Sciences 5(2): 65-74.
23. Trivedi MK, Sethi KK, Panda P, Jana S (2017) A comprehensive physicochemical, thermal, and spectroscopic characterization of zinc (II) chloride using X-ray diffraction, particle size distribution, differential scanning calorimetry, thermogravimetric analysis/differential thermal analysis, ultraviolet-visible, and Fourier transform-infrared spectroscopy. International Journal of Pharmaceutical Investigation 7(1): 33-40.
24. Trivedi MK, Sethi KK, Panda P, Jana S (2017) Physicochemical, thermal and spectroscopic characterization of sodium selenate using XRD, PSD, DSC, TGA/DTG, UV-vis, and FT-IR. Marmara Pharmaceutical Journal 21(2): 311-318.
25. Desktop X-ray Diffractometer “MiniFlex+”. The Rigaku Journal 14: 29-36, 1997.
26. Zhang T, Paluch K, Scalabrino G, Frankish N, Healy AM, et al. (2015) Molecular structure studies of (1S,2S)-2-benzyl-2,3-dihydro-2-(1Hinden-2-yl)-1H-inden-1-ol. MolStruct 1083: 286-289.
27. Langford JL, Wilson AJC (1978) Scherrer after sixty years: A survey and some new results in the determination of crystallite size. J Appl Cryst 11: 102-113.
28. Morin G, Briens L (2013) The Effect of Lubricants on Powder Flowability for pharmaceutical Application. AAPS Pharm Sci Tech 14(3): 1158-1168.
29. Hilnak AJ, Kuriyan K, Morris KR, Reklaitis GW, Basu PK (2006) Understanding critical material properties for solid dosage form design. J Pharm Innov 1(1): 12-17.
30. Inoue M, Hirasawa I (2013) The relationship between crystal morphology and XRD peak intensity on CaSO\textsubscript{4}. J Crystal Growth 380: 169-175.
31. Brittain HG (2009) Polymorphism in pharmaceutical solids in Drugs and Pharmaceutical Sciences, volume 192, 2\textsuperscript{nd}Edn, Informa Healthcare USA, Inc, New York.
32. Raza K, Kumar P, Ratan S, Malik R, Arora S (2014) Polymorphism: The phenomenon affecting the performance of drugs. SO Pharz Pharm Sci 1: 10.
33. Zhao Z, Xie M, Li Y, Chen A, Li G, et al. (2015) Formation of curcumin nanoparticles via solution enhanced dispersion by supercritical CO\textsubscript{2}. Int J Nanomedicine 10: 3171-3181.

Your next submission with Juniper Publishers will reach you the below assets

- Quality Editorial service
- Swift Peer Review
- Reprints availability
- E-prints Service
- Manuscript Podcast for convenient understanding
- Global attainment for your research
- Manuscript accessibility in different formats

(Pdf, E-pub, Full Text, Audio)
- Unceasing customer service

Track the below URL for one-step submission
https://juniperpublishers.com/online-submission.php